These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19680146)

  • 21. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
    Brown PJ; Ashe SL; Leich E; Burek C; Barrans S; Fenton JA; Jack AS; Pulford K; Rosenwald A; Banham AH
    Blood; 2008 Mar; 111(5):2816-24. PubMed ID: 18077790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.
    Courts C; Montesinos-Rongen M; Martin-Subero JI; Brunn A; Siemer D; Zühlke-Jenisch R; Pels H; Jürgens A; Schlegel U; Schmidt-Wolf IG; Schaller C; Reifenberger G; Sabel M; Warnecke-Eberz U; Wiestler OD; Küppers R; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2007 Mar; 66(3):230-7. PubMed ID: 17356384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
    van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
    Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type.
    Espinet B; García-Herrera A; Gallardo F; Baró C; Salgado R; Servitje O; Estrach T; Colomo L; Romagosa V; Barranco C; Serrano S; Campo E; Pujol RM; Solé F
    Histol Histopathol; 2011 Feb; 26(2):213-21. PubMed ID: 21154235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma.
    Chen BB; Xu XP; Shen L; Han TJ; Lin ZG; Chen Z; Kang H; Huang B; Lin GW
    Chin Med J (Engl); 2013 Feb; 126(3):482-7. PubMed ID: 23422111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
    Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
    Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center.
    Katna R; Shet T; Sengar M; Menon H; Laskar S; Prabhash K; D'Cruz A; Nair R
    Head Neck; 2013 Feb; 35(2):165-71. PubMed ID: 22368156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Forkhead box P1 overexpression and its clinicopathologic significance in peripheral T-cell lymphoma, not otherwise specified.
    Yamada S; Sato F; Xia H; Takino H; Kominato S; Ri M; Ishida T; Iida S; Inagaki H; Yamada K
    Hum Pathol; 2012 Aug; 43(8):1322-7. PubMed ID: 22401769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma.
    Brunn A; Montesinos-Rongen M; Strack A; Reifenberger G; Mawrin C; Schaller C; Deckert M
    Acta Neuropathol; 2007 Sep; 114(3):271-6. PubMed ID: 17641901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1.
    Rouhigharabaei L; Finalet Ferreiro J; Tousseyn T; van der Krogt JA; Put N; Haralambieva E; Graux C; Maes B; Vicente C; Vandenberghe P; Cools J; Wlodarska I
    PLoS One; 2014; 9(1):e85851. PubMed ID: 24416450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
    Brown PJ; Gascoyne DM; Lyne L; Spearman H; Felce SL; McFadden N; Chakravarty P; Barrans S; Lynham S; Calado DP; Ward M; Banham AH
    Haematologica; 2016 Jul; 101(7):861-71. PubMed ID: 27056922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significant increase in the expression of matrix metalloproteinase 7 in primary CNS lymphoma.
    Matsumoto T; Kumagai J; Hasegawa M; Tamaki M; Aoyagi M; Ohno K; Mizusawa H; Kitagawa M; Eishi Y; Koike M
    Neuropathology; 2008 Jun; 28(3):277-85. PubMed ID: 18179407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.
    Goatly A; Bacon CM; Nakamura S; Ye H; Kim I; Brown PJ; Ruskoné-Fourmestraux A; Cervera P; Streubel B; Banham AH; Du MQ
    Mod Pathol; 2008 Jul; 21(7):902-11. PubMed ID: 18487996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
    Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K
    Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
    D'Haene N; Catteau X; Maris C; Martin B; Salmon I; Decaestecker C
    Br J Haematol; 2008 Feb; 140(4):402-10. PubMed ID: 18081894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas.
    Miles RR; Mankey CC; Seiler CE; Smith LB; Teruya-Feldstein J; Hsi ED; Elenitoba-Johnson KS; Lim MS
    Hum Pathol; 2009 Dec; 40(12):1731-7. PubMed ID: 19716163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.
    Barrans SL; Fenton JA; Ventura R; Smith A; Banham AH; Jack AS
    Haematologica; 2007 Jun; 92(6):863-4. PubMed ID: 17550867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.
    Walker MP; Stopford CM; Cederlund M; Fang F; Jahn C; Rabinowitz AD; Goldfarb D; Graham DM; Yan F; Deal AM; Fedoriw Y; Richards KL; Davis IJ; Weidinger G; Damania B; Major MB
    Sci Signal; 2015 Feb; 8(362):ra12. PubMed ID: 25650440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.